The end of bursectomy for gastric cancer ?
Mené au Japon sur 1 204 patients atteints d'un cancer d'un adénocarcinome gastrique résécable de stade cT3 à cT4a (âge : 20 à 80 ans), cet essai de phase III évalue, du point de vue de l'amélioration de la survie globale, l'intérêt d'ajouter une bursectomie à une omentectomie durant l'intervention chirurgicale
Yukinori Kurokawa and colleagues1 make an important contribution to the surgical management of gastric cancer in their well conducted, multicentre randomised controlled trial published in The Lancet Gastroenterology & Hepatology. The trial addresses the contentious role of bursectomy by assigning patients with resectable gastric cancer to receive either omentectomy with bursectomy or omentectomy alone (non-bursectomy). Only one inconclusive randomised trial has examined this practice previously,2 and Kurokawa and colleagues' much larger trial1 resolves the ongoing uncertainty.
The Lancet Gastroenterology & Hepatology , commentaire, 2017